Corporate Presentation
January 2022
Disclaimer and Forward-Looking Statement
Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the future business and financial performance of Biomea Fusion, Inc. (the "Company") and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. All statements other than statements of historical fact could be deemed forward-looking, including any projections of financial information or profitability, the initiation, timing and results of pending or future preclinical studies and clinical trials, the actual or potential actions of the FDA, the status and timing of ongoing research, development and corporate partnering activities, any statements about historical results that may suggest trends for the Company's business; any statements of the plans, strategies, and objectives of management for future operations; any statements of expectation or belief regarding future events, potential markets or market size, or technology developments, and other factors affecting the Company's financial condition or operations. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this presentation are made only as of the date hereof. Except as required by law, the Company assumes no obligation and does not intend to update these forward-looking statements or to conform these statements to actual results or to changes in the Company's expectations. This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions, and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.
2
Experienced and Successful Management Team
Novel FUSION™ Platform
BMF-219 - Clinical Stage
Oncology Asset
Multiple Oncology Programs built from FUSIONTM Platform
We Aim To Cure
Biomea Fusion is a clinical-stage biopharmaceutical company focused on the discovery and development of irreversible small-molecule drugs to treat patients with genetically defined cancers. We believe that our approach may lead to significant improvement and extension of life for patients. Our team is engaged in all phases of drug discovery and development, including target selection, small molecule design, and preclinical and clinical studies to develop innovative medicines.
3
BMF-219 - Novel Irreversible Covalent Inhibitor of Menin
Pipeline-in-a-Pill - Single Agent for Multiple Indications
Strong Pathway Control
Large effect on target genes and proteins leading to cell death
Multiple Shots on Goal
Acute leukemias, MYC addicted and driven cancers, RAS/RAF driven solid tumors
Consistent On-Target Effect
Pathway control and cell killing seen at same predicted dose across indications
Wide Safety Margin
Strong preclinical safety profile from animal studies
4
Our Team - 10+ Years of Success Together
Thomas Butler Ramses Erdtmann | Franco Valle | Naomi Cretcher | Heow Tan | Steve Morris MD | Thorsten Kirschberg | Jim Palmer | |
Chairman & CEO | President & COO | Chief Financial | Chief of People | Chief Technical & Chief Medical Officer | EVP of Chemistry | VP of Drug | |
Officer | Quality Officer | Consultant | Discovery | ||||
15+ years in Life Science | 15+ years in Life Science | 15+ years in Life Science | 15+ years in Life Science | 22+ years in Life Science | 25+ years in Life Science | 25+ years in Life Science | 30+ years in Life Science |
Pharmacyclics | Pharmacyclics | Eidos Therapeutics | Pharmacyclics | Pharmacyclics | HealthChart LLC | Terns Pharmaceuticals | Biota Ltd |
Gilead Sciences | Oxygen Investments | Iovance Biotherapeutics | Genentech | Collegium Pharmaceutical | Insight Genetics | Gilead Sciences | Cytopia Ltd. |
UCLA - MBA Finance | Commerzbank | Pharmacyclics | UC Irvine, BA Comm | Praecis Pharmaceuticals | St. Jude Children's | Cell Gate | Rigel, Inc. |
UCSB, MS - Chemistry | University of Münster, | CallidusCloud | SF State University, Comm | Ohio State University | Research Hospital | Golden Gate University, | Celera Genomics |
Master's in Banking & | PricewaterhouseCoopers | Santa Clara University | Board certified internist | MBA | Prototek Inc. | ||
Corp Finance | San Jose State University, BS | Leavey School of Business, | (Univ. of Texas SW HSC) | University of Münster, | Purdue University | ||
Corporate Finance | MBA - Finance & Mgmt | and medical oncologist | Ph.D., Chemistry | Ph.D. Organic Chemistry | |||
(Yale University School of | |||||||
Medicine) |
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Biomea Fusion Inc. published this content on 12 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 January 2022 17:15:00 UTC.